查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1146209

肝病诊断市场——增长、趋势、COVID-19 的影响和预测 (2022-2027)

Liver Disease Diagnostics Market - Growth, Trends, and Forecasts (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在 2022 年至 2027 年的预测期内，肝病诊断市场的复合年增长率预计为 5.8%。

COVID-19 对非 COVID-19 疾病的诊断和治疗产生了重大影响，因为所有资源都已转移给 COVID-19 患者。由于禁闭限制和高传染性疾病的可能性，预计对医院和诊所的访问量减少也将对研究市场产生重大影响。然而，据报导，COVID-19 可能对肝病患者产生严重影响，表明对肝病诊断市场具有潜在的积极影响。例如，根据 2021 年 5 月发表的题为“COVID-19 对肝病进展的影响”的研究，严重 COVID-19 的风险与酒精性肝损伤和酒精性肝硬化显着相关。而肝硬化与免疫功能障碍有关，这与 COVID-19 的不良预后有关。因此，COVID-19有望衝击肝病诊断市场。

预计推动肝病诊断市场增长的主要因素是全球酒精消费量的增加和肝病的高患病率。例如，根据 2021 年 6 月发表的题为“全球慢性肝病流行病学”的研究，慢性肝病 (CLD) 是全球死亡和发病的主要原因之一，约有 15 亿人受到影响。此外，根据同一来源，最常见的患病原因是非酒精性脂肪性肝病 (NAFLD) (59%)，其次是乙型肝炎 (29%)、丙型肝炎 (9%) 和酒精性肝病 (NAFLD) (59%). 疾病 (ALD) (2%).同样，根据 2021 年 9 月发表的“乙型肝炎病毒血清学标誌物在医护人员中的全球流行率”研究报告，“乙型肝炎病毒血清学标誌物在医护人员中的全球流行率。肝炎是一个全球性的公共卫生问题，乙型肝炎病毒根据荟萃分析，乙肝病毒 (HBV) 感染每年影响约 20 亿人并导致 100 万人死亡。此外，根据同一消息来源，医护人员 (HCW) 感染乙肝病毒的风险很高，因为他们的职业涉及接触患者的血液。因此，由于肝病负担沉重，预计对肝病诊断产品的需求将增加，预计将推动研究市场的增长。

此外，酒精摄入量增加和肥胖等肝病相关风险因素预计将进一步对市场产生积极影响，因为这些因素预计将推动对肝病诊断产品的需求。例如，根据 2021 年 12 月发表的题为“COVID-19 大流行期间饮酒量增加对酒精相关肝病的影响”的研究，在 COVID-19 大流行期间，酒精相关肝病的饮酒量增加。一项建模研究发现，在 COVID-19 大流行期间，酒精消费的短暂增加显着增加了与 ALD 相关的长期发病率和死亡率，美国的酒精消费量增加了高达 25%。根据同一份文件，到 2040 年，消费量的增加将导致酒精性肝病死亡人数增加 8,000 人，肝衰竭病例增加 18,700 人，肝癌病例增加 1,000 人。对有效和先进诊断工具的需求预计将增长，因此可以进行该治疗。因此，由于上述因素，肝病诊断市场有望在预测期内增长。然而，与肝病检测相关的高成本预计将在预测期内抑制研究市场的增长。

主要市场趋势

在预测期内，影像检测细分市场将占据较大份额

由于与用于诊断肝病的其他诊断技术相比，成像测试具有很高的特异性，因此预计该市场将出现显着增长。超声、放射性核素扫描、计算机断层扫描（CT）、磁共振成像（MRI）、内窥镜逆行胰胆管造影（ERCP）、经皮经肝胆管造影、肝臟外科胆管造影、这是胆囊和胆道的图像处理方法。影像学检查可帮助医生准确地检查肝臟并检测肝臟的早期形态变化。成像测试被广泛使用，因此有望在预测期内见证健康增长。例如，2022 年，美国国家医学图书馆宣布梯度反射回波 (GRE) MRI 是检测肝脂肪变性存在和严重程度的最准确成像方式。

此外，肝臟成像市场的主要参与者正在提高意识并促进各种肝病的早期诊断以及新产品的开发和发布，这些新产品有望进一步推动研究领域的增长。我们相互合作前进。例如，2022 年 6 月，Echosense 和Novo Nordisk将合作采用非酒精性脂肪性肝炎 (NASH) 的无创诊断测试，以提高对该疾病的认识以及早期诊断和管理的重要性。正在与两家公司希望到 2025 年将晚期至严重 NASH 的诊断率提高一倍。因此，由于上述因素，肝病诊断市场的影像检测板块预计在预测期内将占据较大份额。

预计在预测期内北美将占据主要市场份额

北美地区预计将主导市场，原因包括肝病患病率高、饮酒量高以及先进和强大的医疗基础设施的存在。例如，根据加拿大肝臟基金会2021年的报告，2020年，非酒精性脂肪肝是最常见的肝臟疾病，影响超过700万人，而肝癌是加拿大增长最快的疾病，使其成为最致命的癌症。因此，由于疾病的早期发现推动了北美地区研究市场的增长，预计该地区对肝病诊断产品的需求很高。

在北美地区，由于肝病负担高以及相关的风险因素（如大量饮酒和肥胖），预计美国将主导市场。例如，根据美国疾病控制与预防中心 2022 年 1 月的更新，该国约有 480 万人被诊断患有肝病。此外，根据同一份数据，该国的酒精消费量也很高，是增加肝病负担的主要因素之一，约25.1%的18岁及以上成年人的酒精消费量在1%左右。前一年。我有 5 天或更多男性大量饮酒，女性 4 天或更多。因此，我国肝病负担有望逐年加重，有望对市场产生积极影响。此外，随着公司在市场上推出新的高级测试，人们的健康意识不断提高，预计将对所研究的市场产生进一步的积极影响。例如，2022 年 1 月，Siemens Healthmeyers 在美国推出了增强型肝纤维化 (ELF) 测试，这是一种从头上市的 ELF 测试，用于评估非酒精性脂肪性肝炎 (NASH) 患者的疾病进展。这是最早的测试之一预后血液测试获得批准。因此，由于上述因素，预计北美地区将占据较大的市场份额，其中美国将是预测期内肝病诊断市场的主要市场。

竞争格局

由于多家公司在全球和区域开展业务，因此肝病诊断市场分散且竞争激烈。该行业的主要公司包括 Abbott Laboratories、F. Hoffmann-La Roche Ltd、Thermo Fisher Scientific Inc、Randox Laboratories Ltd、Boston Scientific Corporation、Laboratory Corporation of America Holdings、Siemens Healthcare GmbH、BioMerieux SA、Quest Diagnostics Incorporated、Biosino Bio -Technology and Science Inc 和 Echosens。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 饮酒量增加
    • 肝病患病率增加
  • 市场製约因素
    • 诊断测试成本高
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 通过诊断技术
    • 肝活检
    • 图像检查
    • 肝功能检查
    • 内窥镜检查
  • 最终用户
    • 医院
    • 研究所
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Abbott
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Randox Laboratories Ltd.
    • Boston Scientific Corporation
    • Laboratory Corporation of America Holdings
    • Siemens Healthcare GmbH
    • BioMerieux SA
    • Quest Diagnostics Incorporated
    • Biosino Bio-Technology and Science Inc

第七章市场机会与未来趋势

简介目录
Product Code: 91559

The liver disease diagnostics market is expected to register a CAGR of 5.8% over the forecast period, 2022-2027.

COVID-19 had a significant impact on the diagnosis and treatment of diseases other than COVID-19 as all the resources were diverted for the COVID-19 patients and also, due to lockdown restrictions and high chances of contracting infection, the footfall in the hospitals and clinics reduced for diseases other than COVID-19 which was expected to have a significant impact on the studied market. However, it was reported that COVID-19 may have a severe impact on people with liver diseases which might have a positive impact on the liver disease diagnostics market. For instance, according to a research study published in May 2021, titled "Impact of COVID-19 in Liver Disease Progression", the risk of severe COVID-19 was significantly associated with alcoholic liver damage and alcoholic liver cirrhosis, and also, cirrhosis is associated with immune dysfunction, which is related to a bad COVID-19 prognosis. Hence, COVID-19 is anticipated to have an impact on the liver disease diagnostics market.

The major factors that are expected to fuel growth in the liver disease diagnostics market are the increasing consumption of the alcohol and high prevalence of liver diseases around the world. For instance, according to the research study published in June 2021, titled "Global Epidemiology of Chronic Liver Disease", chronic liver disease (CLD) is one of the leading causes of mortality and morbidity around the world and affects about 1.5 billion people across the world. Further, as per the same source, the most common causes of prevalent disease are non-alcoholic fatty liver disease (NAFLD) (59%), followed by hepatitis B (29%), hepatitis C (9%), and alcoholic liver disease (ALD) (2%). Similarly, according to a research study published in September 2021, titled "Global Prevalence of Hepatitis B Virus Serological Markers Among Healthcare Workers: A Systematic Review and Meta-Analysis", hepatitis is a global public health issue, and the hepatitis B virus (HBV) infection affects around 2 billion individuals and results in 1 million fatalities each year. Also, as per the same source, healthcare workers (HCWs) are at high risk for HBV because of the occupational risk to patient blood. Hence, due to the high burden of liver diseases, the demand for liver disease diagnostics products is expected to increase which is anticipated to drive growth in the studied market.

In addition, the increasing consumption of alcohol and an associated risk factor for liver disease like obesity is further expected to have a positive impact on the market as these factors are expected to boost the demand for liver disease diagnostics products. For instance, according to a research study published in December 2021, titled "Effect of Increased Alcohol Consumption During COVID-19 Pandemic on Alcohol-Associated Liver Disease: A Modeling Study", during the COVID-19 pandemic, a temporary rise in alcohol intake can significantly raise long-term ALD-related morbidity and mortality, and it was observed that the alcohol consumption increases up to 25% in the United States. Also, as per the same source, this increase in consumption can lead to 8,000 additional deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer by 2040, which is expected to increase the demand for effective and advanced diagnostic tools so that appropriate medical attention can be provided to the patient. Therefore, due to the above-mentioned factors, the liver disease diagnostics market is expected to grow over the forecast period. However, high costs associated with liver disease tests are expected to restrain the growth of the studied market over the forecast period.

Key Market Trends

Imaging Tests Segment is Expected to Hold a Significant Share in the Market Over the forecast Period

The imaging segment is expected to have significant growth in the market due to its high specificity when compared with other diagnostic techniques used in liver disease diagnostics. Ultrasonography, radionuclide scanning, computed tomography (CT), magnetic resonance imaging (MRI), endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography, and surgical cholangiography are imaging procedures for the liver, gallbladder, and biliary tract. The imaging tests help doctors with an accurate examination of the liver enabling them to early detection of morphological changes in the liver the imaging tests are used widely and hence, are expected to have a healthy growth over the forecast period. For instance, in 2022, the National Library of Medicine of the United States published that gradient recalled echo (GRE) MRI is the most accurate imaging method to detect the existence and severity of hepatic steatosis.

Additionally, the key players in the market of liver imaging diagnostics are partnering with each other to increase awareness and advance the early diagnosis of various liver diseases along with the development and launch of new products which are further expected to boost growth in the studied segment. For instance, in June 2022, Echosens and Novo Nordisk collaborated on the adoption of non-invasive diagnostic tests for non-alcoholic steatohepatitis (NASH) and work together to increase awareness of the disease and the importance of early diagnosis and management. By 2025, the firms hope to have doubled the rate of diagnoses for those with advanced to severe NASH. Therefore, due to the above-mentioned factors, the imaging tests segment in the liver disease diagnostics market is expected to have a significant share over the forecast period.

North America Region is Expected Occupy Major Share in the Market Over the Forecast Period

North American region is expected to dominate the market due to factors such as the high prevalence of liver diseases, high-alcohol consumption, the presence of advanced and robust healthcare infrastructure, and other factors. For instance, according to the 2021 report of the Canadian Liver Foundation, in 2020, non-alcoholic fatty liver disease was the most common liver disease, affecting over 7 million people and liver cancer is the fastest rising and deadliest form of cancer in Canada. Thus, the demand for liver disease diagnostics products in the region is expected to be high for the early detection of the disease which will fuel growth in the studied market in the North America region.

In the North American region, the United States is expected to dominate the market owing to the high burden of liver diseases and associated risk factors such as high consumption of alcohol and obesity. For instance, according to the January 2022 update of the Centers for Disease Control and Prevention, about 4.8 million people in the country are living with diagnosed liver disease. Further, as per the same source, alcohol consumption is also very high in the country which is one of the major factors responsible for the increase in the burden of liver disease and about 25.1% of adults of age 18 and more had approximately one heavy drinking day (five or more drinks for men and four or more drinks for women) in the previous years. Hence, the burden of liver diseases in the country is expected to increase over the years which is anticipated to have a positive impact on the market. Moreover, the growing health awareness along with the launch of new and advanced tests by the companies in the market is further expected to have a positive impact on the studied market. For instance, in January 2022, Siemens Healthineers launched enhanced liver fibrosis (ELF) test in the United States and the ELF test is one of the first prognostic blood tests granted De Novo marketing authorization to assess disease progression in non-alcoholic steatohepatitis (NASH) patients. Therefore, owing to the above-mentioned factors, the North American region is expected to hold a significant market share, in which the United States will be a major market for the liver disease diagnostics market over the forecast period.

Competitive Landscape

The liver disease diagnostics market is fragmented in nature due to the presence of several companies operating globally as well as regionally and thus, it is moderately competitive. SOme of the key companies operating in the industry are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Randox Laboratories Ltd, Boston Scientific Corporation, Laboratory Corporation of America Holdings, Siemens Healthcare GmbH, BioMerieux SA, Quest Diagnostics Incorporated, Biosino Bio-Technology and Science Inc, and Echosens.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Alcohol Consumption
    • 4.2.2 Increase in Prevalence of Liver Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Diagnostic Test
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Diagnosis Technique
    • 5.1.1 Liver Biopsy
    • 5.1.2 Imaging Tests
    • 5.1.3 Liver Function Tests
    • 5.1.4 Endoscopy
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Laboratories
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 F. Hoffmann-La Roche Ltd.
    • 6.1.3 Thermo Fisher Scientific Inc.
    • 6.1.4 Randox Laboratories Ltd.
    • 6.1.5 Boston Scientific Corporation
    • 6.1.6 Laboratory Corporation of America Holdings
    • 6.1.7 Siemens Healthcare GmbH
    • 6.1.8 BioMerieux SA
    • 6.1.9 Quest Diagnostics Incorporated
    • 6.1.10 Biosino Bio-Technology and Science Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS